ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Trial record **1 of 1** for: TMC435350-TiDP16-C201
Previous Study | Return to List | Next Study

# A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

**This study has been completed.**

**Sponsor:**
Tibotec Pharmaceuticals, Ireland

**Information provided by (Responsible Party):**
Tibotec Pharmaceuticals, Ireland

**ClinicalTrials.gov Identifier:**
NCT00561353

First received: November 19, 2007
Last updated: May 14, 2014
Last verified: May 2014
History of Changes

Full Text View | Tabular View | Study Results | Disclaimer | How to Read a Study Record

Results First Received: December 18, 2013

| | |
|---|---|
| **Study Type:** | Interventional |
| **Study Design:** | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study;<br>Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator);<br>Primary Purpose: Treatment |
| **Condition:** | Hepatitis C, Chronic |
| **Interventions:** | Drug: TMC435<br>Drug: Placebo<br>Drug: Peginterferon (PegIFNα-2a)<br>Drug: Ribavirin |

## Participant Flow

Hide Participant Flow

### Recruitment Details

| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| The study was conducted at 25 sites in 6 countries: Belgium, France, Germany, Poland, the Netherlands, and the United Kingdom. |

### Pre-Assignment Details

| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| A total of 121 participants infected with Hepatitis C virus (HCV) were randomized of whom 116 were treated. Reasons for not receiving treatment were withdrawal of consent (4 participants) and sponsor's decision (1 participant). |

### Reporting Groups

| | Description |
|---|---|
| **TMC435 25 mg (Cohort 1/Panel A and B)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) OR TMC435 25 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 75mg (Cohort 1/Panel A and B)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **Placebo (Cohort 1/Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 200 mg (Cohort 2, Panel A and B)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 |

| | |
|---|---|
| | (Panel B) |
| **Placebo (Cohort 2/Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 75 mg (Cohort 4/Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4/Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4/Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 4/Panel C)** | Treatment-experienced non-responders received placebo (identical in appearance to TMC435 75 mg, 150 mg, or 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5/Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Participant Flow: Overall Study**

| | TMC435 25 mg (Cohort 1/Panel A and B) | TMC435 75mg (Cohort 1/Panel A and B) | Placebo (Cohort 1/Panel A and B) | TMC435 200 mg (Cohort 2, Panel A and B) | Placebo (Cohort 2/Panel A and B) | TMC435 75 mg (Cohort 4/Panel C) | TMC435 150 mg (Cohort 4/Panel C) | TMC435 200 mg (Cohort 4/Panel C) | Placebo (Cohort 4/Panel C) | TMC435 200 mg (Cohort 5/Panel D) |
|---|---|---|---|---|---|---|---|---|---|---|
| **STARTED** | 18 | 19 | 13 | 18 | 6 | 9 | 9 | 10 | 9 | 5 |
| **COMPLETED** | 13 | 16 | 10 | 12 | 5 | 3 | 3 | 6 | 2 | 3 |
| **NOT COMPLETED** | 5 | 3 | 3 | 6 | 1 | 6 | 6 | 4 | 7 | 2 |
| Subject reached a virologic endpoint | 2 | 1 | 1 | 4 | 1 | 3 | 4 | 4 | 5 | 0 |
| Subject ineligible to continue the trial | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 1 |
| Not specified | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Adverse Event | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 |
| Lost to Follow-up | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrawal by Subject | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

## Baseline Characteristics

Hide Baseline Characteristics

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| No text entered. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 25 mg (Cohort 1)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) OR TMC435 25 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |

| | |
|---|---|
| **TMC435 75mg (Cohort 1)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **Placebo (Cohort 1)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 200 mg (Cohort 2)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **Placebo (Cohort 2)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 75 mg (Cohort 4)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 4)** | Treatment-experienced non-responders received placebo (identical in appearance to TMC435 75 mg, 150 mg, or 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Total** | Total of all reporting groups |

**Baseline Measures**

| | TMC435 25 mg (Cohort 1) | TMC435 75mg (Cohort 1) | Placebo (Cohort 1) | TMC435 200 mg (Cohort 2) | Placebo (Cohort 2) | TMC435 75 mg (Cohort 4) | TMC435 150 mg (Cohort 4) | TMC435 200 mg (Cohort 4) | Placebo (Cohort 4) | TMC435 200 mg (Cohort 5) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Number of Participants [units: participants]** | **18** | **19** | **13** | **18** | **6** | **9** | **9** | **10** | **9** | **5** | **116** |
| **Age [units: years] Median (Full Range)** | **52 (22 to 64)** | **47 (22 to 70)** | **45 (19 to 60)** | **46.5 (19 to 68)** | **44.5 (19 to 50)** | **53 (38 to 62)** | **56 (32 to 67)** | **55.5 (28 to 69)** | **47 (21 to 57)** | **56 (33 to 66)** | **49 (19 to 70)** |
| **Gender [units: participants]** | | | | | | | | | | | |
| **Female** | **5** | **8** | **3** | **8** | **1** | **3** | **1** | **2** | **0** | **0** | **31** |
| **Male** | **13** | **11** | **10** | **10** | **5** | **6** | **8** | **8** | **9** | **5** | **85** |
| **The Number of Participants Randomized to each Treatment Panel [1] [units: participants]** | | | | | | | | | | | |
| **Panel A** | **9** | **10** | **6** | **9** | **3** | **0** | **0** | **0** | **0** | **0** | **37** |
| **Panel B** | **9** | **9** | **7** | **9** | **3** | **0** | **0** | **0** | **0** | **0** | **37** |
| **Panel C** | **0** | **0** | **0** | **0** | **0** | **9** | **9** | **10** | **9** | **0** | **37** |
| **Panel D** | **0** | **0** | **0** | **0** | **0** | **0** | **0** | **0** | **0** | **5** | **5** |

[1] The table below shows the number of participants in Cohorts 1, 2, 4 and 5 that were randomized to treatment Panels A, B, C, and D.

## Outcome Measures

Hide All Outcome Measures

1. Primary: Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A) [ Time Frame: Week 4 ]

| | |
|---|---|
| **Measure Type** | Primary |

| | |
|---|---|
| **Measure Title** | Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A) |
| **Measure Description** | The table below shows the change from Baseline in plasma levels of HCV RNA at Week 4 following treatment with TMC435 or placebo as for 7 days followed by TMC435 or placebo coadministered with ribavirin for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22 in treatment-naïve HCV-infected participants. (A treatment-naive participant is someone who has never taken drugs for their HCV infection). |
| **Time Frame** | Week 4 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **Placebo (Cohort 1, Panel A)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 or 75 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel A)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **Placebo (Cohort 2, Panel A)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |

**Measured Values**

| | **TMC435 25 mg (Cohort 1, Panel A)** | **TMC435 75 mg (Cohort 1, Panel A)** | **Placebo (Cohort 1, Panel A)** | **TMC435 200 mg (Cohort 2, Panel A)** | **Placebo (Cohort 2, Panel A)** |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **10** | **6** | **9** | **3** |
| **Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A) [units: log10 IU/mL] Mean (Standard Error)** | **-4.26 (0.646)** | **-4.47 (0.489)** | **-2.97 (0.640)** | **-4.70 (0.584)** | **-1.92 (0.156)** |

**No statistical analysis provided for Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A)**

2. Primary: Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B) [ Time Frame: Week 4 ]

| | |
|---|---|
| **Measure Type** | Primary |
| **Measure Title** | Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B) |
| **Measure Description** | The table below shows the change from Baseline in plasma levels of HCV RNA at Week 4 following treatment with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22 in treatment-naïve HCV-infected participants. (A treatment-naive participant is someone who has never taken drugs for their HCV infection). |
| **Time Frame** | Week 4 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|

The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses.

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 25 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 1, Panel B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel B)** | Treatment-naïve participants received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 2, Panel B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 25 mg (Cohort 1, Panel B) | TMC435 75 mg (Cohort 1, Panel B) | Placebo (Cohort 1, Panel B) | TMC435 200 mg (Cohort 2, Panel B) | Placebo (Cohort 2, Panel B) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **7** | **9** | **3** |
| **Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B) [units: log10 IU/mL] Mean (Standard Error)** | **-4.74 (0.455)** | **-5.52 (0.228)** | **-3.74 (0.665)** | **-5.44 (0.169)** | **-3.26 (1.222)** |

**No statistical analysis provided for Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B)**

3. Primary: Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Week 4 ]

| | |
|---|---|
| **Measure Type** | Primary |
| **Measure Title** | Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows the change from Baseline in plasma levels of HCV RNA at Week 4 following treatment with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22 in treatment-experienced participants considered non-responders (defined as participants who achieved less than a 2 log10 IU/mL decline from baseline in plasma HCV RNA levels after 12 weeks of previous interferon [IFN]-based therapy [pegylated or non-pegylated]) or relapsers (defined as a participant with undetectable plasma HCV RNA at the end of treatment of previous IFN-based therapy and subsequent confirmed detectable plasma HCV RNA levels during follow-up). |
| **Time Frame** | Week 4 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

| | |
|---|---|
| **Placebo (Cohort 4, Panel C)** | Treatment-experienced non-responders received placebo (identical in appearance to TMC435 75 mg, 150 mg, or 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 75 mg (Cohort 4, Panel C) | TMC435 150 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 4, Panel C) | Placebo (Cohort 4, Panel C) | TMC435 200 mg (Cohort 5, Panel D) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **10** | **9** | **4** |
| **Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: log10 IU/mL] Mean (Standard Error)** | **-4.28 (0.539)** | **-5.46 (0.425)** | **-5.26 (0.238)** | **-1.53 (0.216)** | **-5.86 (0.198)** |

**No statistical analysis provided for Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

4. Secondary: Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A) [ Time Frame: Day 7 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A) |
| **Measure Description** | The table below shows the change from Baseline in plasma levels of HCV RNA on Day 7 (at Week 1) following treatment with TMC435 or placebo for 7 days followed by TMC435 or placebo coadministered with ribavirin for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 in treatment-naïve HCV-infected participants. (A treatment-naive participant is someone who has never taken drugs for their HCV infection). |
| **Time Frame** | Day 7 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **Placebo (Cohort 1, Panel A)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 or 75 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel A)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **Placebo (Cohort 2, Panel A)** | Treatment-naïve participants in received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |

**Measured Values**

| | TMC435 25 mg (Cohort 1, Panel A) | TMC435 75 mg (Cohort 1, Panel A) | Placebo (Cohort 1, Panel A) | TMC435 200 mg (Cohort 2, Panel A) | Placebo (Cohort 2, Panel A) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **10** | **6** | **9** | **3** |

| | | | | | |
|---|---|---|---|---|---|
| **Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A)<br>[units: log10 IU/mL]<br>Mean (Standard Error)** | **-2.63 (0.377)** | **-3.48 (0.285)** | **-0.08 (0.101)** | **-4.18 (0.158)** | **0.30 (0.080)** |

**No statistical analysis provided for Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A)**

5. Secondary: Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B) [ Time Frame: Day 7 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B) |
| **Measure Description** | The table below shows the change from Baseline in plasma levels of HCV RNA on Day 7 (at Week 1) following treatment with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22 in treatment-naïve HCV-infected participants (A treatment-naive participant is someone who has never taken drugs for their HCV infection). |
| **Time Frame** | Day 7 |
| **Safety Issue** | No |

**Population Description**

| |
|---|
| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 25 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 1, Panel B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel B)** | Treatment-naïve participants received TMC435 200 mg once daily for 28 days coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 2, Panel B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | **TMC435 25 mg (Cohort 1, Panel B)** | **TMC435 75 mg (Cohort 1, Panel B)** | **Placebo (Cohort 1, Panel B)** | **TMC435 200 mg (Cohort 2, Panel B)** | **Placebo (Cohort 2, Panel B)** |
|---|---|---|---|---|---|
| **Number of Participants Analyzed<br>[units: participants]** | **9** | **9** | **7** | **9** | **3** |
| **Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B)<br>[units: log10 IU/mL]<br>Mean (Standard Error)** | **-3.47 (0.500)** | **-4.55 (0.192)** | **-1.73 (0.441)** | **-4.68 (0.135)** | **-1.64 (0.793)** |

**No statistical analysis provided for Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B)**

6. Secondary: Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Day 7 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows the change from Baseline in plasma levels of HCV RNA on Day 7 (Week 1) following treatment with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22 in treatment-experienced participants considered non-responders (defined as participants who achieved less than a 2 log10 IU/mL decline from baseline in plasma HCV RNA levels after 12 weeks of previous interferon [IFN]-based therapy [pegylated or non-pegylated]) or relapsers (defined as a participant with undetectable plasma HCV RNA at the end of treatment of previous IFN-based therapy and subsequent confirmed detectable plasma HCV RNA levels during follow-up). |
| **Time Frame** | Day 7 |
| **Safety Issue** | No |

**Population Description**

| |
|---|
| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 4, Panel C)** | Treatment-experienced non-responders received placebo (identical in appearance to TMC435 75 mg, 150 mg, or 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | **TMC435 75 mg (Cohort 4, Panel C)** | **TMC435 150 mg (Cohort 4, Panel C)** | **TMC435 200 mg (Cohort 4, Panel C)** | **Placebo (Cohort 4, Panel C)** | **TMC435 200 mg (Cohort 5, Panel D)** |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **10** | **9** | **5** |
| **Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: log10 IU/mL] Mean (Standard Error)** | **-3.80 (0.432)** | **-4.68 (0.224)** | **-4.49 (0.318)** | **-0.50 (0.152)** | **-4.08 (0.387)** |

**No statistical analysis provided for Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

7. Secondary: Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A) [ Time Frame: Day 2 or 3, Day 7, and Day 28 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A) |
| **Measure Description** | The table below shows the number of treatment-naïve HCV-infected participants treated with TMC435 or placebo for 7 days followed by TMC435 or placebo coadministered with ribavirin for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 who had the following virologic responses: plasma levels of HCV ribonucleic acid (RNA) of greater than or equal to 2 log10 decline from Baseline; plasma levels of HCV RNA below the limit of quantification (ie, less than [<] 25 IU/mL detectable or undetectable); plasma levels of HCV RNA below the limit of detection (ie, <25 IU/mL undetectable); plasma levels of HCV RNA <100 IU/mL; and plasma levels of HCV RNA <1000 at the time points listed. See "treatment-naive" defined above. |
| **Time Frame** | Day 2 or 3, Day 7, and Day 28 |

| | |
|---|---|
| **Safety Issue** | No |

**Population Description**

| |
|---|
| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **Placebo (Cohort 1, Panel A)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 or 75 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel A)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **Placebo (Cohort 2, Panel A)** | Treatment-naïve participants in received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |

**Measured Values**

| | TMC435 25 mg (Cohort 1, Panel A) | TMC435 75 mg (Cohort 1, Panel A) | Placebo (Cohort 1, Panel A) | TMC435 200 mg (Cohort 2, Panel A) | Placebo (Cohort 2, Panel A) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **10** | **6** | **9** | **3** |
| **Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A) [units: Participants]** | | | | | |
| **Day 2/3: > or = 2 log10 change from baseline** | **6** | **9** | **0** | **9** | **0** |
| **Day 7: > or = 2 log10 change from baseline** | **7** | **9** | **0** | **9** | **0** |
| **Day 28: > or = 2 log10 change from baseline** | **7** | **9** | **4** | **8** | **1** |
| **Day 2/3: <25 IU/mL detectable or undetectable** | **1** | **1** | **0** | **1** | **0** |
| **Day 7: <25 IU/mL detectable or undetectable** | **1** | **0** | **0** | **1** | **0** |
| **Day 28: <25 IU/mL detectable or undetectable** | **5** | **8** | **1** | **7** | **0** |
| **Day 2/3: <25 IU/mL undetectable** | **0** | **0** | **0** | **0** | **0** |
| **Day 7: <25 IU/mL undetectable** | **0** | **0** | **0** | **0** | **0** |
| **Day 28: <25 IU/mL undetectable** | **5** | **5** | **1** | **7** | **0** |
| **Day 2/3: <100 IU/mL** | **1** | **1** | **0** | **1** | **0** |
| **Day 7: <100 IU/mL** | **1** | **3** | **0** | **4** | **0** |
| **Day 28: <100 IU/mL** | **6** | **8** | **1** | **7** | **0** |
| **Day 2/3: <1000 IU/mL** | **2** | **5** | **0** | **6** | **0** |
| **Day 7: <1000 IU/mL** | **3** | **6** | **0** | **7** | **0** |
| **Day 28: <1000 IU/mL** | **7** | **8** | **2** | **7** | **0** |

**No statistical analysis provided for Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)**

8. Secondary: Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B) [ Time Frame: Day 2 or 3, Day 7, and Day 28 ]

| | |
|---|---|
| **Measure Type** | Secondary |

| | |
|---|---|
| **Measure Title** | Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B) |
| **Measure Description** | The table below shows the number of treatment-naive HCV-Infected participants with the following virologic responses to treatment with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22: plasma levels of HCV ribonucleic acid (RNA) of greater than or equal to 2 log10 decline from Baseline; plasma levels of HCV RNA below the limit of quantification (ie, less than [<] 25 IU/mL detectable or undetectable); plasma levels of HCV RNA below the limit of detection (ie, <25 IU/mL undetectable); plasma levels of HCV RNA <100 IU/mL; and plasma levels of HCV RNA <1000 at the time points listed. See "treatment-naive" defined above. |
| **Time Frame** | Day 2 or 3, Day 7, and Day 28 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 25 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 1, Panel B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg and 75 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel B)** | Treatment-naïve participants received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 2, Panel B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | **TMC435 25 (Cohort 1, Panel B)** | **TMC435 75 mg (Cohort 1, Panel B)** | **Placebo (Cohort 1, Panel B)** | **TMC435 200 mg (Cohort 2, Panel B)** | **Placebo (Cohort 2, Panel B)** |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **7** | **9** | **3** |
| **Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B) [units: Participants]** | | | | | |
| **Day 2/3: > or = 2 log10 change from baseline** | **7** | **9** | **2** | **9** | **2** |
| **Day 7: > or = 2 log10 change from baseline** | **7** | **9** | **2** | **9** | **1** |
| **Day 28: > or = 2 log10 change from baseline** | **8** | **9** | **6** | **9** | **2** |
| **Day 2/3: <25 IU/mL detectable or undetectable** | **0** | **0** | **0** | **0** | **0** |
| **Day 7: <25 IU/mL detectable or undetectable** | **1** | **1** | **0** | **3** | **0** |
| **Day 28: <25 IU/mL detectable or undetectable** | **6** | **9** | **3** | **9** | **1** |
| **Day 2/3: <25 IU/mL undetectable** | **0** | **0** | **0** | **0** | **0** |
| **Day 7: <25 IU/mL undetectable** | **0** | **0** | **0** | **1** | **0** |
| **Day 28: <25 IU/mL undetectable** | **3** | **8** | **2** | **6** | **0** |
| **Day 2/3: <100 IU/mL** | **0** | **1** | **0** | **1** | **0** |
| **Day 7: <100 IU/mL** | **1** | **6** | **0** | **5** | **0** |
| **Day 28: <100 IU/mL** | **6** | **9** | **3** | **9** | **1** |
| **Day 2/3: <1000 IU/mL** | **4** | **5** | **0** | **6** | **0** |
| **Day 7: <1000 IU/mL** | **5** | **9** | **0** | **9** | **0** |
| **Day 28: <1000 IU/mL** | **7** | **9** | **4** | **9** | **2** |

**No statistical analysis provided for Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants**

**(Cohort 1 and 2, Panel B)**

9. Secondary: Virologic Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Day 2 or 3, Day 7, and Day 28 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Virologic Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows the number of treatment-experienced participants (non-responders and relapsers, see defined above) with the following virologic responses to treatment with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22: plasma levels of HCV ribonucleic acid (RNA) of greater than or equal to 2 log10 decline from Baseline; plasma levels of HCV RNA below the limit of quantification (ie, less than [<] 25 IU/mL detectable or undetectable); plasma levels of HCV RNA below the limit of detection (ie, <25 IU/mL undetectable); plasma levels of HCV RNA <100 IU/mL; and plasma levels of HCV RNA <1000 at the time points listed. Note: in the table below, the number of participants (n) analyzed in the TMC435 200 mg (Cohort 4, Panel B) on Day 28 (Week 4) was n=4. |
| **Time Frame** | Day 2 or 3, Day 7, and Day 28 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 4, Panel C)** | Treatment-experienced non-responders received placebo (identical in appearance to TMC435 75 mg, 150 mg, or 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | **TMC435 75 mg (Cohort 4, Panel C)** | **TMC435 150 mg (Cohort 4, Panel C)** | **TMC435 200 mg (Cohort 4, Panel C)** | **Placebo (Cohort 4, Panel C)** | **TMC435 200 mg (Cohort 5, Panel D)** |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **10** | **9** | **5** |
| **Virologic Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: Participants]** | | | | | |
| **Day 2/3: > or = 2 log10 change from baseline** | **8** | **9** | **10** | **1** | **4** |
| **Day 7: > or = 2 log10 change from baseline** | **8** | **9** | **10** | **0** | **5** |
| **Day 28: > or = 2 log10 change from baseline** | **8** | **9** | **10** | **2** | **4** |
| **Day 2/3: <25 IU/mL detectable or undetectable** | **0** | **0** | **0** | **0** | **0** |
| **Day 7: <25 IU/mL detectable or undetectable** | **0** | **2** | **3** | **0** | **0** |
| **Day 28: <25 IU/mL detectable or undetectable** | **4** | **7** | **7** | **0** | **4** |
| **Day 2/3: <25 IU/mL undetectable** | **0** | **0** | **0** | **0** | **0** |
| **Day 7: <25 IU/mL undetectable** | **0** | **0** | **0** | **0** | **0** |
| **Day 28: <25 IU/mL undetectable** | **2** | **5** | **3** | **0** | **3** |
| **Day 2/3: <100 IU/mL** | **0** | **0** | **0** | **0** | **0** |

| | | | | | |
|---|---|---|---|---|---|
| **Day 7: <100 IU/mL** | **2** | **4** | **5** | **0** | **0** |
| **Day 28: <100 IU/mL** | **6** | **8** | **7** | **0** | **4** |
| **Day 2/3: <1000 IU/mL** | **3** | **3** | **5** | **0** | **0** |
| **Day 7: <1000 IU/mL** | **5** | **7** | **8** | **0** | **3** |
| **Day 28: <1000 IU/mL** | **6** | **8** | **10** | **0** | **4** |

**No statistical analysis provided for Virologic Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

10. Secondary: Virologic Response Parameters in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined) [ Time Frame: Week 4 (RVR), Week 12 (EVR, cEVR, and partial response), and Week 4 and 12 (eRVR) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Virologic Response Parameters in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined) |
| **Measure Description** | The table below shows the number of treatment-naïve participants in the treatment groups for Cohort 1 (Panel A and B combined) and in Cohort 2 (Panel A and B combined) who met the following virologic response parameters: rapid virological response (RVR) defined as having undetectable plasma HCV ribonucleic acid (RNA) at Week 4; early virologic response (EVR) defined as change from baseline in plasma HCV RNA of greater than or equal to 2 log 10 at Week 12); a complete EVR (cEVR) defined as a complete EVR having undetectable plasma HCV RNA at Week 12); an extended RVR (eRVR) defined as undetectable plasma HCV RNA at Week 4 and 12; and a partial response defined as EVR but not reaching undetectability while on treatment. |
| **Time Frame** | Week 4 (RVR), Week 12 (EVR, cEVR, and partial response), and Week 4 and 12 (eRVR) |
| **Safety Issue** | No |

**Population Description**

| |
|---|
| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A and B)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) OR TMC435 25 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **TMC435 75mg (Cohort 1, Panel A and B)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **Placebo (Cohort 1, Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily for 7 days followed RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **TMC435 200mg (Cohort 2, Panel A and B)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **Placebo (Cohort 2, Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |

**Measured Values**

| | **TMC435 25 mg (Cohort 1, Panel A and B)** | **TMC435 75mg (Cohort 1, Panel A and B)** | **Placebo (Cohort 1, Panel A and B)** | **TMC435 200mg (Cohort 2, Panel A and B)** | **Placebo (Cohort 2, Panel A and B)** |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **18** | **19** | **13** | **18** | **6** |
| **Virologic Response Parameters in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)** | | | | | |

| [units: Participants] | | | | | |
|---|---|---|---|---|---|
| RVR | 8 | 13 | 3 | 13 | 0 |
| EVR | 16 | 19 | 12 | 16 | 6 |
| cEVR | 13 | 17 | 7 | 16 | 5 |
| eRVR | 8 | 13 | 3 | 13 | 0 |
| Partial response | 0 | 0 | 0 | 0 | 1 |

**No statistical analysis provided for Virologic Response Parameters in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)**

11. Secondary: Virologic Response Parameters Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Week 4 (RVR), Week 12 (EVR, cEVR, and partial response), and Week 4 and 12 (eRVR) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Virologic Response Parameters Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows the number of treatment-experienced participants (non-responders and relapsers, see defined above) treated with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22 who met the following virologic response parameters: rapid virological response (RVR) defined as having undetectable plasma HCV ribonucleic acid (RNA) at Week 4; early virologic response (EVR) defined as change from baseline in plasma HCV RNA of greater than or equal to 2 log 10 at Week 12; a complete EVR (cEVR) defined as a EVR having undetectable plasma HCV RNA at Week 12; an extended RVR (eRVR) defined as undetectable plasma HCV RNA at Week 4 and 12; and a partial response defined as EVR but not reaching undetectability while on treatment. |
| **Time Frame** | Week 4 (RVR), Week 12 (EVR, cEVR, and partial response), and Week 4 and 12 (eRVR) |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 4, Panel C)** | Treatment-experienced non-responders received placebo (identical in appearance to TMC435 75 mg, 150 mg, or 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 75 mg (Cohort 4, Panel C) | TMC435 150 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 4, Panel C) | Placebo (Cohort 4, Panel C) | TMC435 200 mg (Cohort 5, Panel D) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | 9 | 9 | 10 | 9 | 5 |
| **Virologic Response Parameters Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: Participants]** | | | | | |
| RVR | 2 | 5 | 3 | 0 | 3 |
| EVR | 6 | 7 | 8 | 8 | 4 |

| | | | | | |
|---|---|---|---|---|---|
| **cEVR** | **4** | **4** | **5** | **0** | **3** |
| **eRVR** | **2** | **4** | **3** | **0** | **3** |
| **Partial response** | **0** | **1** | **1** | **5** | **0** |

**No statistical analysis provided for Virologic Response Parameters Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

12. Secondary: Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A) [ Time Frame: Day 2 or 3 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A) |
| **Measure Description** | The table below shows the number of treatment-naïve participants with an initial suboptimal response defined as less than 2 log10 change in plasma level of hepatitis C virus (HCV) ribonucleic acid (RNA) on Day 2 or 3 (depending when visit was scheduled) following treatment with TMC435 or placebo for 7 days followed by TMC435 or placebo coadministered with ribavirin for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22. See "treatment-naive" defined above. |
| **Time Frame** | Day 2 or 3 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **Placebo (Cohort 1, Panel A)** | Treatment-naïve participants received placebo identical in appearance toTMC435 25 or 75 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel A)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **Placebo (Cohort 2, Panel A)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |

**Measured Values**

| | **TMC435 25 mg (Cohort 1, Panel A)** | **TMC435 75 mg (Cohort 1, Panel A)** | **Placebo (Cohort 1, Panel A)** | **TMC435 200 mg (Cohort 2, Panel A)** | **Placebo (Cohort 2, Panel A)** |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **10** | **6** | **9** | **3** |
| **Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A) [units: Participants]** | **3** | **1** | **6** | **0** | **3** |

**No statistical analysis provided for Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)**

13. Secondary: Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B) [ Time Frame: Day 2 or 3 ]

| | |
|---|---|
| **Measure Type** | Secondary |

| | |
|---|---|
| **Measure Title** | Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B) |
| **Measure Description** | The table below shows the number of treatment-naïve participants with an initial suboptimal response defined as less than 2 log10 change in plasma plasma level of hepatitis C virus (HCV) ribonucleic acid (RNA) on Day 2 or 3 (depending when visit was scheduled) after treatment with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. See "treatment-naive" defined above. |
| **Time Frame** | Day 2 or 3 |
| **Safety Issue** | No |

**Population Description**

| |
|---|
| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
| The intent-to-treat (ITT) population, defined as all participants who were randomized and received at least one dose of study medication (TMC435) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 25 mg coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 75 mg once daily for 28 days coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 1, Panel B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel B)** | Treatment-naïve participants received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 2, Panel B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | **TMC435 25 mg (Cohort 1, Panel B)** | **TMC435 75 mg (Cohort 1, Panel B)** | **Placebo (Cohort 1, Panel B)** | **TMC435 200 mg (Cohort 2, Panel B)** | **Placebo (Cohort 2, Panel B)** |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **7** | **9** | **3** |
| **Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B) [units: Participants]** | **2** | **0** | **5** | **0** | **1** |

**No statistical analysis provided for Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)**

14. Secondary: Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Day 2 or 3 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows the number of treatment-experienced participants (non-responders and relapsers, see defined above) with an initial suboptimal response defined as less than 2 log10 change of plasma in plasma level of HCV ribonucleic acid (RNA) at Day 2 or 3 (depending when visit was scheduled) treated with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **Time Frame** | Day 2 or 3 |
| **Safety Issue** | No |

**Population Description**

| |
|---|
| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all |

analyses.

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 4, Panel C)** | Treatment-experienced non-responders received placebo (identical in appearance to TMC435 75 mg, 150 mg, or 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 75 mg (Cohort 4, Panel C) | TMC435 150 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 4, Panel C) | Placebo (Cohort 4, Panel C) | TMC435 200 mg (Cohort 5, Panel D) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **10** | **9** | **5** |
| **Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: Participants]** | **1** | **0** | **0** | **8** | **1** |

**No statistical analysis provided for Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

15. Secondary: Viral Breakthrough in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1, Panel A and B) [ Time Frame: 4 Weeks (Wks), 44 Wks, and 48 Wks ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Viral Breakthrough in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1, Panel A and B) |
| **Measure Description** | The table below shows the number of treatment-naïve participants with viral breakthrough, defined as a confirmed increase of greater than 1 log10 IU/mL in plasma HCV ribonucleic acid (RNA) level from the lowest level reached, or a confirmed plasma HCV RNA level of greater than 100 IU/mL in participants whose plasma HCV RNA had previously been below the limit of quantification (25 IU/mL detectable) or undetectable (less than 25 IU/mL undetectable) after treatment with TMC435 or placebo for 7 days followed by TMC435 or placebo coadministered with ribavirin for 21 days + peginterferon alpha-2a (PegIFNα-2a) on days 8, 15, and 22 (Panel A) and after treatment with TMC435 or placebo coadministered with ribavirin for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **Time Frame** | 4 Weeks (Wks), 44 Wks, and 48 Wks |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. Note: Number of participants analyzed during the PegIFNα-2a and ribavirin treatment period of up to 44 weeks is N=16 for TMC435 25 mg, N=17 for TMC435 75 mg, and N=17 for TMC435 200 mg. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 25 mg (Cohort 1, Panels A and B)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) OR TMC435 25 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **TMC435 75 mg (Cohort 1, Panels A and B)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 |

| | |
|---|---|
| | (Panel B). |
| **Placebo (Cohort 1, Panels A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily for 7 days followed RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **TMC435 200 mg (Cohort 2, Panels A and B)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **Placebo (Cohort 2, Panels A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |

**Measured Values**

| | TMC435 25 mg (Cohort 1, Panels A and B) | TMC435 75 mg (Cohort 1, Panels A and B) | Placebo (Cohort 1, Panels A and B) | TMC435 200 mg (Cohort 2, Panels A and B) | Placebo (Cohort 2, Panels A and B) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **18** | **19** | **13** | **18** | **6** |
| **Viral Breakthrough in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1, Panel A and B) [units: Participants]** | | | | | |
| **Entire treatment period (48 Wks)** | **3** | **3** | **0** | **4** | **0** |
| **During TMC435/Placebo treatment (4 Wks)** | **2** | **2** | **0** | **1** | **0** |
| **During treatment with RBV and PegIFNα-2a (44 Wks)** | **1** | **1** | **0** | **3** | **0** |

**No statistical analysis provided for Viral Breakthrough in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1, Panel A and B)**

16. Secondary: Viral Breakthrough in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: 4 Weeks (Wks), 44 Wks, and 48 Wks ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Viral Breakthrough in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows the number of treatment-experienced participants (non-responders and relapsers, see defined above) with viral breakthrough, defined as a confirmed increase of greater than 1 log10 IU/mL in plasma HCV ribonucleic acid (RNA) level from the lowest level reached), or a confirmed plasma HCV RNA level of greater than 100 IU/mL in participants whose plasma HCV RNA had previously been below the limit of quantification (25 IU/mL detectable) or undetectable (less than 25 IU/mL undetectable) treated with TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **Time Frame** | 4 Weeks (Wks), 44 Wks, and 48 Wks |
| **Safety Issue** | No |

**Population Description**

| |
|---|
| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| | |

| | |
|---|---|
| **Placebo (TMC435 75/150/200 mg) (Cohort 4, Panel C)** | Treatment-experienced non-responders received Placebo identical in appearance to TMC435 75 mg, 150 mg, or 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 75 mg (Cohort 4, Panel C) | TMC435 150 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 4, Panel C) | Placebo (TMC435 75/150/200 mg) (Cohort 4, Panel C) | TMC435 200 mg (Cohort 5, Panel D) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **10** | **9** | **5** |
| **Viral Breakthrough in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: Participants]** | | | | | |
| **Entire treatment period (48 Wks)** | **3** | **4** | **4** | **1** | **1** |
| **During TMC435/Placebo treatment (4 Wks)** | **2** | **1** | **0** | **1** | **0** |
| **During treatment with RBV and PegIFNα-2a (44 Wks)** | **1** | **3** | **4** | **0** | **1** |

**No statistical analysis provided for Viral Breakthrough in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

17. Secondary: Viral Relapse in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined) [ Time Frame: Up to Week 72 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Viral Relapse in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined) |
| **Measure Description** | The table below shows the number of treatment-naïve participants with viral relapse (defined as having confirmed detectable plasma level of HCV ribonucleic acid [RNA] during the follow-up period in participants with undetectable plasma HCV RNA [less than 25 IU/mL undetectable] at the end of treatment) for the treatment groups in Cohort 1 (Panel A and B combined) and in Cohort 2 (Panel A and B combined). See "treatment-naïve" defined above. |
| **Time Frame** | Up to Week 72 |
| **Safety Issue** | No |

**Population Description**

| |
|---|
| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
| The analysis population used to evaluate viral relapse included participants in the intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) who were treatment-naïve and had undetectable plasma HCV RNA (less than 25 IU/mL undetectable) at the end of treatment. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A and B)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) OR TMC435 25 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **TMC435 75 mg (Cohort 1, Panel A and B)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **Placebo (Cohort 1, Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily for 7 days followed by Placebo once daily coadministered with RBV for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **TMC435 200 mg (Cohort 2, Panel A and B)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |

| | |
|---|---|
| **Placebo (Cohort 2, Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |

**Measured Values**

| | TMC435 25 mg (Cohort 1, Panel A and B) | TMC435 75 mg (Cohort 1, Panel A and B) | Placebo (Cohort 1, Panel A and B) | TMC435 200 mg (Cohort 2, Panel A and B) | Placebo (Cohort 2, Panel A and B) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **15** | **18** | **12** | **14** | **5** |
| **Viral Relapse in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined) [units: Participants]** | | | | | |
| **Relapse** | **2** | **1** | **2** | **1** | **0** |
| **No relapse** | **12** | **17** | **10** | **13** | **5** |
| **Missing follow-up** | **1** | **0** | **0** | **0** | **0** |

**No statistical analysis provided for Viral Relapse in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)**

18. Secondary: Viral Relapse in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Up to Week 72 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Viral Relapse in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows the number of treatment-experienced participants combined (non-responders and relapsers, see defined above) with viral relapse, defined as having confirmed detectable plasma level of HCV ribonucleic acid (RNA) during the follow-up period in participants with undetectable plasma HCV RNA (less than 25 IU/mL undetectable) at the end of treatment who received TMC435 or placebo coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **Time Frame** | Up to Week 72 |
| **Safety Issue** | No |

**Population Description**

| |
|---|
| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
| The analysis population used to evaluate viral relapse included participants in the intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) who were treatment-experienced and had undetectable plasma HCV RNA (less than 25 IU/mL undetectable) at the end of treatment. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (TMC435 75/150/200 mg) (Cohort 4, Panel C)** | Treatment-experienced non-responders received Placebo identical in appearance to TMC435 75 mg, 150 mg, or 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers in Cohort 5, Panel D received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 75 mg (Cohort 4, Panel C) | TMC435 150 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 4, Panel C) | Placebo (TMC435 75/150/200 mg) (Cohort 4, Panel C) | TMC435 200 mg (Cohort 5, Panel D) |
|---|---|---|---|---|---|
| | | | | | |

| | | | | | |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **6** | **3** | **6** | **3** | **3** |
| **Viral Relapse in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: Participants]** | | | | | |
| **Relapse** | **3** | **0** | **1** | **3** | **0** |
| **No relapse** | **3** | **3** | **5** | **0** | **3** |

**No statistical analysis provided for Viral Relapse in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

19. Secondary: Sustained Virologic Response (SVR) in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined) [ Time Frame: SVR4 (Week 52), SVR8 (Week 56), SVR12 (Week 60), and SVR24 (Week 72) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Sustained Virologic Response (SVR) in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined) |
| **Measure Description** | The table below shows the number of treatment-naïve participants with an SVR to treatment (defined as having an undetectable plasma level of HCV ribonucleic acid after the last planned dose of treatment) for the treatment groups in Cohort 1 (Panel A and B combined) and in Cohort 2 (Panel A and B combined). SVR was measured at 4, 8, 12, and 24 weeks after the last dose of treatment (SVR4, SVR8, SVR12, and SVR24, respectively). See "treatment-naïve" defined above. |
| **Time Frame** | SVR4 (Week 52), SVR8 (Week 56), SVR12 (Week 60), and SVR24 (Week 72) |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A and B)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) OR TMC435 25 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **TMC435 75mg (Cohort 1, Panel A and B)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **Placebo (Cohort 1, Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily for 7 days followed by Placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **TMC435 200mg (Cohort 2, Panel A and B)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |
| **Placebo (Cohort 2, Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). |

**Measured Values**

| | **TMC435 25 mg (Cohort 1, Panel A and B)** | **TMC435 75mg (Cohort 1, Panel A and B)** | **Placebo (Cohort 1, Panel A and B)** | **TMC435 200mg (Cohort 2, Panel A and B)** | **Placebo (Cohort 2, Panel A and B)** |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **18** | **19** | **13** | **18** | **6** |
| **Sustained Virologic Response (SVR) in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)** | | | | | |

| [units: Participants] | | | | | |
|---|---|---|---|---|---|
| SVR4 | 12 | 16 | 11 | 12 | 5 |
| SVR8 | 12 | 14 | 9 | 12 | 5 |
| SVR12 | 12 | 15 | 9 | 12 | 5 |
| SVR24 | 10 | 15 | 9 | 12 | 5 |

**No statistical analysis provided for Sustained Virologic Response (SVR) in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)**

20. Secondary: Sustained Virologic Response (SVR) in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: SVR4 (Week 52), SVR8 (Week 56), SVR12 (Week 60), and SVR24 (Week 72) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Sustained Virologic Response (SVR) in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows the number of treatment-experienced participants (non-responders and relapsers, see defined above) in each treatment group in Cohort 4, Panel C and in Cohort 5, Panel D with an SVR to treatment defined as having an undetectable plasma level of HCV ribonucleic acid after the last planned dose of the entire treatment regimen. SVR was measured at 4, 8, 12, and 24 weeks after the last dose of treatment (SVR4, SVR8, SVR12, and SVR24, respectively). |
| **Time Frame** | SVR4 (Week 52), SVR8 (Week 56), SVR12 (Week 60), and SVR24 (Week 72) |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The intent-to-treat population (defined as all participants who were randomized and received at least one dose of study medication) was used for all analyses. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (TMC435 75/150/200 mg) (Cohort 4, Panel C)** | Treatment-experienced non-responders received Placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 75 mg (Cohort 4, Panel C) | TMC435 150 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 4, Panel C) | Placebo (TMC435 75/150/200 mg) (Cohort 4, Panel C) | TMC435 200 mg (Cohort 5, Panel D) |
|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | 9 | 9 | 10 | 9 | 5 |
| **Sustained Virologic Response (SVR) in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: Participants]** | | | | | |
| SVR4 | 2 | 3 | 4 | 1 | 3 |
| SVR8 | 1 | 3 | 4 | 0 | 3 |
| SVR12 | 1 | 3 | 5 | 0 | 3 |
| SVR24 | 1 | 3 | 5 | 0 | 3 |

**No statistical analysis provided for Sustained Virologic Response (SVR) in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

21. Secondary: Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) [ Time Frame: Days 1 and 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) |
| **Measure Description** | The table below shows the mean (standard deviation) Cmax for treatment-naïve participants at selected time points who were treated with TMC435 for 7 days followed by TMC435 coadministered with ribavirin for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) and with TMC435 coadministered with ribavirin for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). See "treatment-naïve" defined above. The number of participants analyzed at Day 28 in the 6 treatment groups listed below from left to right were 9, 8, 7, 9, 9, and 10. |
| **Time Frame** | Days 1 and 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| All participants who received treatment were included in the pharmacokinetic (PK) analysis, however, due to various reasons (ie, missing samples at certain time points, or exclusion of specific plasma concentrations from the PK analysis) not all PK parameters could always be calculated for each participant. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel A)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 25 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 25 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel B)** | Treatment-naïve participants received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | **TMC435 25 mg (Cohort 1, Panel A)** | **TMC435 75 mg (Cohort 1, Panel A)** | **TMC435 200 mg (Cohort 2, Panel A)** | **TMC435 25 mg (Cohort 1, Panel B)** | **TMC435 75 mg (Cohort 1, Panel B)** | **TMC435 200 mg (Cohort 2, Panel B)** |
|---|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **10** | **8** | **9** | **8** | **10** |
| **Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) [units: ng/mL] Mean (Standard Deviation)** | | | | | | |
| **Day 1** | **251.1 (77.40)** | **1008 (490.9)** | **3369 (1760)** | **239.6 (125.8)** | **958.0 (448.9)** | **3945 (2096)** |
| **Day 28** | **307.1 (88.16)** | **1058 (547.5)** | **11180 (8522)** | **329.4 (186.9)** | **1609 (1310)** | **10900 (6974)** |

**No statistical analysis provided for Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)**

22. Secondary: Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Days 1 and 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows the mean (standard deviation) Cmax for treatment-experienced participants (non-responders and relapsers, see defined above) following treatment with TMC435 coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. The number of participants analyzed at Day 28 in the 4 treatment groups listed below from left to right were 8, 8, 10, and 3. |
| **Time Frame** | Days 1 and 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| All participants who received treatment were included in the pharmacokinetic (PK) analysis, however, due to various reasons (ie, missing samples at certain time points, or exclusion of specific plasma concentrations from the PK analysis) not all PK parameters could always be calculated for each participant. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | **TMC435 75 mg (Cohort 4, Panel C)** | **TMC435 150 mg (Cohort 4, Panel C)** | **TMC435 200 mg (Cohort 4, Panel C)** | **TMC435 200 mg (Cohort 5, Panel D)** |
|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **9** | **4** |
| **Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: ng/mL] Mean (Standard Deviation)** | | | | |
| **Day 1** | **882.1 (273.2)** | **2422 (919.0)** | **2877 (1399)** | **3870 (565.0)** |
| **Day 28** | **1481 (879.6)** | **4383 (2374)** | **8452 (6112)** | **12220 (2917)** |

**No statistical analysis provided for Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

23. Secondary: Predose Plasma Concentration (C0h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) [ Time Frame: Day 2 (predose) and Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Predose Plasma Concentration (C0h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) |
| **Measure Description** | The table below shows mean (standard deviation) of C0h of TMC435 at selected time points following treatment with TMC435 for 7 days followed by TMC435 coadministered with ribavirin for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) or with TMC435 coadministered with ribavirin for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) in treatment-naïve participants (see "treatment-naïve" defined above).The number of participants analyzed at Day 28 in the 6 treatment groups listed below from left to right were 9, 9, 8, 9, 9, and 10. |

| | |
|---|---|
| **Time Frame** | Day 2 (predose) and Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| All participants who received treatment were included in the pharmacokinetic (PK) analysis, however, due to various reasons (ie, missing samples at certain time points, or exclusion of specific plasma concentrations from the PK analysis) not all PK parameters could always be calculated for each participant. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel A)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 25 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 25 mg coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 75 mg once daily for 28 days coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel B)** | Treatment-naïve participants received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | **TMC435 25 mg (Cohort 1, Panel A)** | **TMC435 75 mg (Cohort 1, Panel A)** | **TMC435 200 mg (Cohort 2, Panel A)** | **TMC435 25 mg (Cohort 1, Panel B)** | **TMC435 75 mg (Cohort 1, Panel B)** | **TMC435 200 mg (Cohort 2, Panel B)** |
|---|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **8** | **9** | **8** | **9** | **9** | **10** |
| **Predose Plasma Concentration (C0h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) [units: ng/ml] Mean (Standard Deviation)** | | | | | | |
| **Day 2** | **64.51 (37.57)** | **209.3 (107.4)** | **1053 (526.5)** | **65.73 (41.75)** | **281.6 (288.1)** | **821.7 (422.9)** |
| **Day 28** | **64.78 (35.15)** | **331.6 (326.6)** | **6913 (7726)** | **95.83 (61.56)** | **632.8 (1128)** | **4818 (5071)** |

**No statistical analysis provided for Predose Plasma Concentration (C0h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)**

24. Secondary: Predose Plasma Concentration (C0h) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Day 2 (predose) and Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Predose Plasma Concentration (C0h) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows mean (standard deviation) of C0h for treatment-experienced participants (non-responders and relapsers, see defined above) following treatment with TMC435 coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. The number of participants analyzed at Day 2 and Day 28 differed as follows: At Day 2, the number of participants in the 4 treatment groups (from left to right) were 8, 7, 10, and 5; the number of participants analyzed at Day 28 in the 4 treatment groups (from left to right) were 9, 8, 10, and 4. |
| **Time Frame** | Day 2 (predose) and Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) |
| **Safety Issue** | No |

**Population Description**

| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| All participants who received treatment were included in the pharmacokinetic (PK) analysis, however, due to various reasons (ie, missing samples at certain time points, or exclusion of specific plasma concentrations from the PK analysis) not all PK parameters could always be calculated for each participant. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 75 mg (Cohort 4, Panel C) | TMC435 150 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 5, Panel D) |
|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **8** | **10** | **5** |
| **Predose Plasma Concentration (C0h) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: ng/mL] Mean (Standard Deviation)** | | | | |
| **Day 2** | **278.4 (192.2)** | **733.6 (436.4)** | **669.8 (301.7)** | **1280 (955.8)** |
| **Day 28** | **324.3 (351.9)** | **1431 (1501)** | **4145 (4425)** | **5593 (3817)** |

**No statistical analysis provided for Predose Plasma Concentration (C0h) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

25. Secondary: Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) [ Time Frame: Day 7 (predose); Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) (Panel A, Cohorts 1 and 2) and Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) (Panel B, Cohorts 1 and 2) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) |
| **Measure Description** | The table below shows mean (standard deviation)of Css,av for TMC435 in treatment-naïve HCV-infected participants at selected time points administered TMC435 for 7 days followed by TMC435 coadministered with ribavirin for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) and with TMC435 coadministered with ribavirin for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B). See "treatment-naïve" defined above. The number of participants analyzed at Day 28 in the 6 treatment groups listed below from left to right were 9, 8, 7, 9, 9, and 10. |
| **Time Frame** | Day 7 (predose); Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) (Panel A, Cohorts 1 and 2) and Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) (Panel B, Cohorts 1 and 2) |
| **Safety Issue** | No |

**Population Description**

| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| All participants who received treatment were included in the pharmacokinetic (PK) analysis, however, due to various reasons (ie, missing samples at certain time points, or exclusion of specific plasma concentrations from the PK analysis) not all PK parameters could always be calculated for each participant. |

**Reporting Groups**

| | Description |
|---|---|

| | |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TTMC435 200 mg (Cohort 2, Panel A)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 25 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 25 mg coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 75 mg once daily for 28 days coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel B)** | Treatment-naïve participants received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 25 mg (Cohort 1, Panel A) | TMC435 75 mg (Cohort 1, Panel A) | TTMC435 200 mg (Cohort 2, Panel A) | TMC435 25 mg (Cohort 1, Panel B) | TMC435 75 mg (Cohort 1, Panel B) | TMC435 200 mg (Cohort 2, Panel B) |
|---|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **9** | **9** | **7** | **9** | **10** | **10** |
| **Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) [units: ng/ml] Mean (Standard Deviation)** | | | | | | |
| **Day 7** | **180.9 (90.04)** | **832.3 (415.1)** | **5714 (4157)** | **NA [1]** | **NA [1]** | **NA [1]** |
| **Day 28** | **170.4 (62.42)** | **681.4 (414.7)** | **7117 (6699)** | **186.5 (115.7)** | **986.0 (1087)** | **7182 (5415)** |

**[1]** Value not measured

**No statistical analysis provided for Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)**

26. Secondary: Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows mean (standard deviation) of Css,av for TMC435 in treatment-experienced HCV-infected participants (non-responders and relapsers, see defined above) at selected time points following treatment with TMC435 coadministered with ribavirin for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **Time Frame** | Day 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| All participants who received treatment were included in the pharmacokinetic (PK) analysis, however, due to various reasons (ie, missing samples at certain time points, or exclusion of specific plasma concentrations from the PK analysis) not all PK parameters could always be calculated for each participant. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

| | |
|---|---|
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 75 mg (Cohort 4, Panel C) | TMC435 150 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 5, Panel D) |
|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | **8** | **7** | **10** | **3** |
| **Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [units: ng/ml] Mean (Standard Deviation)** | **820.8 (580.1)** | **2435 (1909)** | **6353 (5313)** | **9613 (3981)** |

**No statistical analysis provided for Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

27. Secondary: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) [ Time Frame: Days 1 and 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) |
| **Measure Description** | The table below shows mean (standard deviation) values of the area under the plasma concentration-time curve from time of administration to 24 hours after dosing for TMC435 in treatment-naïve HCV-infected participants administered TMC435 for 7 days followed by TMC435 coadministered with ribavirin for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) and with TMC435 coadministered with ribavirin for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B).The number of participants analyzed at Day 28 in the 6 treatment groups listed below from left to right were 9, 8, 7, 9, 9, and 10. |
| **Time Frame** | Days 1 and 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| All participants who received treatment were included in the pharmacokinetic (PK) analysis, however, due to various reasons (ie, missing samples at certain time points, or exclusion of specific plasma concentrations from the PK analysis) not all PK parameters could always be calculated for each participant. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 25 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel A)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel A)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22. |
| **TMC435 25 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 25 mg coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 75 mg (Cohort 1, Panel B)** | Treatment-naïve participants received TMC435 75 mg once daily for 28 days coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 2, Panel B)** | Treatment-naïve participants received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 | TMC435 | TMC435 | TMC435 | TMC435 | TMC435 |
|---|---|---|---|---|---|---|

| | 25 mg (Cohort 1, Panel A) | 75 mg (Cohort 1, Panel A) | 200 mg (Cohort 2, Panel A) | 25 mg (Cohort 1, Panel B) | 75 mg (Cohort 1, Panel B) | 200 mg (Cohort 2, Panel B) |
|---|---|---|---|---|---|---|
| **Number of Participants Analyzed [units: participants]** | 9 | 10 | 8 | 9 | 8 | 10 |
| **Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B) [units: ng.h/mL] Mean (Standard Deviation)** | | | | | | |
| Day 1 | 3035 (1205) | 12240 (5663) | 43430 (22280) | 2853 (1207) | 12790 (7888) | 45700 (24160) |
| Day 28 | 3961 (1523) | 16600 (10680) | 167200 (154500) | 4527 (2806) | 23610 (26780) | 169400 (126500) |

**No statistical analysis provided for Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)**

28. Secondary: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) [ Time Frame: Days 1 and 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D) |
| **Measure Description** | The table below shows mean (standard deviation) values of the area under the plasma concentration-time curve from time of administration to 24 hours after dosing for TMC435 in treatment-experienced HCV-infected participants considered non-responders (participants who achieved less than a 2 log10 IU/mL decline from baseline in plasma HCV ribonucleic acid (RNA) levels after 12 weeks of previous interferon [IFN]-based therapy [pegylated or non-pegylated]) or relapsers (defined as a participant with undetectable plasma HCV RNA at the end of treatment of previous IFN-based therapy and subsequent confirmed detectable plasma HCV RNA levels during follow-up at selected time points following treatment with TMC435 coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. The number of participants analyzed at Day 28 in the 4 treatment groups listed below from left to right was 8, 7, 10, and 3. |
| **Time Frame** | Days 1 and 28 (predose and 0.5, 1, 2, 4, 6, 8, and 10 hours postdose) |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| All participants who received treatment were included in the pharmacokinetic (PK) analysis, however, due to various reasons (ie, missing samples at certain time points, or exclusion of specific plasma concentrations from the PK analysis) not all PK parameters could always be calculated for each participant. |

**Reporting Groups**

| | **Description** |
|---|---|
| **TMC435 75 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with ribavirin (RBV) for 28 days + peginterferon alpha-2a (PegIFNα-2a) on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4, Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5, Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |

**Measured Values**

| | TMC435 75 mg (Cohort 4, Panel C) | TMC435 150 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 4, Panel C) | TMC435 200 mg (Cohort 5, Panel D) |
|---|---|---|---|---|
| **Number of Participants Analyzed** | 9 | 9 | 9 | 4 |

| [units: participants] | | | | |
|---|---|---|---|---|
| **Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**<br>**[units: ng.h/mL]**<br>**Mean (Standard Deviation)** | | | | |
| **Day 1** | **11150 (2903)** | **30920 (13450)** | **34410 (14440)** | **51300 (16720)** |
| **Day 28** | **20150 (14720)** | **57440 (44730)** | **152600 (126600)** | **231300 (96890)** |

**No statistical analysis provided for Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)**

## Serious Adverse Events

Hide Serious Adverse Events

| | |
|---|---|
| **Time Frame** | Up to 72 weeks. |
| **Additional Description** | No text entered. |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 25 mg (Cohort 1/Panel A and B)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) OR TMC435 25 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 75mg (Cohort 1/Panel A and B)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **Placebo (Cohort 1/Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 200 mg (Cohort 2, Panel A and B)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **Placebo (Cohort 2/Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 75 mg (Cohort 4/Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4/Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4/Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 4/Panel C)** | Treatment-experienced non-responders received placebo (identical in appearance to TMC435 75 mg, 150 mg, or 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5/Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **All TMC435 (All Cohorts)** | No text entered. |

**Serious Adverse Events**

| | TMC435 25 mg (Cohort 1/Panel A and B) | TMC435 75mg (Cohort 1/Panel A and B) | Placebo (Cohort 1/Panel A and B) | TMC435 200 mg (Cohort 2, Panel A and B) | Placebo (Cohort 2/Panel A and B) | TMC435 75 mg (Cohort 4/Panel C) | TMC435 150 mg (Cohort 4/Panel C) | TMC435 200 mg (Cohort 4/Panel C) | Placebo (Cohort 4/Panel C) | Tl 20 (C 5/Pa |
|---|---|---|---|---|---|---|---|---|---|---|

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| **Total, serious adverse events** | | | | | | | | | | |
| **# participants affected / at risk** | **2/18 (11.11%)** | **3/19 (15.79%)** | **3/13 (23.08%)** | **3/18 (16.67%)** | **0/6 (0.00%)** | **1/9 (11.11%)** | **1/9 (11.11%)** | **2/10 (20.00%)** | **0/9 (0.00%)** | **1/5 (** |
| **Blood and lymphatic system disorders** | | | | | | | | | | |
| **Neutropenia** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **1/9 (11.11%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Thrombocytopenia** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **1/9 (11.11%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Cardiac disorders** | | | | | | | | | | |
| **Sinus arrest** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Ear and labyrinth disorders** | | | | | | | | | | |
| **Cupulolithiasis** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **1/10 (10.00%)** | **0/9 (0.00%)** | **0/5** |
| **Endocrine disorders** | | | | | | | | | | |
| **Hyperthyroidism** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **1/18 (5.56%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Infections and infestations** | | | | | | | | | | |
| **Bronchitis** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **1/18 (5.56%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Erysipelas** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Gastroenteritis viral** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **1/5 (** |
| **Pneumonia** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **1/13 (7.69%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Pneumonia escherichia** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **1/13 (7.69%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Sepsis** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **1/9 (11.11%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| **Sinusitis** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **1/13 (7.69%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Metabolism and nutrition disorders** | | | | | | | | | | |
| **Diabetes mellitus insulin-dependent** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **1/19 (5.26%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Musculoskeletal and connective tissue disorders** | | | | | | | | | | |
| **Exostosis** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **1/18 (5.56%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Toe deformity** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **1/18 (5.56%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Neoplasms benign, malignant and unspecified (incl cysts and polyps)** | | | | | | | | | | |
| **Bowen's disease** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **1/9 (11.11%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Breast cancer** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **1/9 (11.11%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Psychiatric disorders** | | | | | | | | | | |
| **Panic attack** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **1/13 (7.69%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Panic reaction** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **1/10 (10.00%)** | **0/9 (0.00%)** | **0/5** |
| **Psychotic disorder** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **1/19 (5.26%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Social circumstances** | | | | | | | | | | |
| **Drug abuser** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **1/19 (5.26%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |
| **Social stay hospitalisation** [*1] | | | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **1/13 (7.69%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** | **0/9 (0.00%)** | **0/5** |

* Events were collected by non-systematic assessment

1 Term from vocabulary, MedDRA Version 10.1

## Other Adverse Events

Hide Other Adverse Events

| | |
|---|---|
| **Time Frame** | Up to 72 weeks. |
| **Additional Description** | No text entered. |

**Frequency Threshold**

| | |
|---|---|
| **Threshold above which other adverse events are reported** | 5% |

**Reporting Groups**

| | Description |
|---|---|
| **TMC435 25 mg (Cohort 1/Panel A and B)** | Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with ribavirin (RBV) for 21 days + peginterferon alpha-2a (PegIFNα-2a) on Days 8, 15, and 22 (Panel A) OR TMC435 25 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 75mg (Cohort 1/Panel A and B)** | Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **Placebo (Cohort 1/Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 25 mg or 75 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 200 mg (Cohort 2, Panel A and B)** | Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **Placebo (Cohort 2/Panel A and B)** | Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with RBV for 21 days + PegIFNα-2a on Days 8, 15, and 22 (Panel A) OR placebo once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22 (Panel B) |
| **TMC435 75 mg (Cohort 4/Panel C)** | Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 150 mg (Cohort 4/Panel C)** | Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 4/Panel C)** | Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **Placebo (Cohort 4/Panel C)** | Treatment-experienced non-responders received placebo (identical in appearance to TMC435 75 mg, 150 mg, or 200 mg) once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **TMC435 200 mg (Cohort 5/Panel D)** | Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with RBV for 28 days + PegIFNα-2a on Days 1, 8, 15, and 22. |
| **All TMC435 (All Cohorts)** | No text entered. |

**Other Adverse Events**

| | TMC435 25 mg (Cohort 1/Panel A and B) | TMC435 75mg (Cohort 1/Panel A and B) | Placebo (Cohort 1/Panel A and B) | TMC435 200 mg (Cohort 2, Panel A and B) | Placebo (Cohort 2/Panel A and B) | TMC435 75 mg (Cohort 4/Panel C) | TMC435 150 mg (Cohort 4/Panel C) | TMC435 200 mg (Cohort 4/Panel C) |
|---|---|---|---|---|---|---|---|---|
| **Total, other (not including serious) adverse events** | | | | | | | | |
| **# participants affected / at risk** | **18/18 (100.00%)** | **19/19 (100.00%)** | **13/13 (100.00%)** | **18/18 (100.00%)** | **6/6 (100.00%)** | **8/9 (88.89%)** | **9/9 (100.00%)** | **10/10 (100.00%)** |
| **Blood and lymphatic system disorders** | | | | | | | | |
| **Anaemia** * 1 | | | | | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| # participants affected / at risk | 3/18 (16.67%) | 2/19 (10.53%) | 3/13 (23.08%) | 5/18 (27.78%) | 1/6 (16.67%) | 3/9 (33.33%) | 1/9 (11.11%) | 2/10 (20.00%) |
| Neutropenia [*1] | | | | | | | | |
| # participants affected / at risk | 5/18 (27.78%) | 7/19 (36.84%) | 1/13 (7.69%) | 6/18 (33.33%) | 2/6 (33.33%) | 2/9 (22.22%) | 3/9 (33.33%) | 3/10 (30.00%) |
| Thrombocytopenia [*1] | | | | | | | | |
| # participants affected / at risk | 4/18 (22.22%) | 1/19 (5.26%) | 1/13 (7.69%) | 1/18 (5.56%) | 1/6 (16.67%) | 1/9 (11.11%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Leukopenia [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 1/9 (11.11%) | 1/10 (10.00%) |
| Lymphadenopathy [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Pancytopenia [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Cardiac disorders** | | | | | | | | |
| Palpitations [*1] | | | | | | | | |
| # participants affected / at risk | 2/18 (11.11%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Postural orthostatic tachycardia syndrome [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Sinus arrest [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Tachycardia [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| **Ear and labyrinth disorders** | | | | | | | | |
| Vertigo [*1] | | | | | | | | |
| # participants affected / at risk | 4/18 (22.22%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 2/10 (20.00%) |
| Ear discomfort [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Hypoacusis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Inner ear inflammation [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Endocrine disorders** | | | | | | | | |
| Hyperthyroidism [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Hypothyroidism [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Eye disorders** | | | | | | | | |
| Abnormal sensation in eye [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Conjunctivitis** [*1] | | | | | | | | |
| **# participants affected / at risk** | 2/18 (11.11%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Dry eye** [*1] | | | | | | | | |
| **# participants affected / at risk** | 2/18 (11.11%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Eye oedema** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Eye pain** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Ocular hyperaemia** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Photophobia** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Retinal vein occlusion** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Visual acuity reduced** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Gastrointestinal disorders** | | | | | | | | |
| **Abdominal pain** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 2/19 (10.53%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Abdominal pain upper** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 1/19 (5.26%) | 1/13 (7.69%) | 2/18 (11.11%) | 0/6 (0.00%) | 1/9 (11.11%) | 1/9 (11.11%) | 0/10 (0.00%) |
| **Constipation** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 2/13 (15.38%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Diarrhoea** [*1] | | | | | | | | |
| **# participants affected / at risk** | 7/18 (38.89%) | 4/19 (21.05%) | 1/13 (7.69%) | 2/18 (11.11%) | 0/6 (0.00%) | 3/9 (33.33%) | 1/9 (11.11%) | 3/10 (30.00%) |
| **Dry mouth** [*1] | | | | | | | | |
| **# participants affected / at risk** | 3/18 (16.67%) | 4/19 (21.05%) | 1/13 (7.69%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Nausea** [*1] | | | | | | | | |
| **# participants affected / at risk** | 9/18 (50.00%) | 6/19 (31.58%) | 1/13 (7.69%) | 6/18 (33.33%) | 2/6 (33.33%) | 3/9 (33.33%) | 3/9 (33.33%) | 4/10 (40.00%) |
| **Toothache** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 1/19 (5.26%) | 1/13 (7.69%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Vomiting** [*1] | | | | | | | | |
| **# participants affected / at risk** | 3/18 (16.67%) | 2/19 (10.53%) | 1/13 (7.69%) | 2/18 (11.11%) | 2/6 (33.33%) | 1/9 (11.11%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Abdominal distension** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Aphthous stomatitis** [*1] | | | | | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| # participants affected / at risk | 1/18 (5.56%) | 2/19 (10.53%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Bowel sounds abnormal [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Breath odour [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Cheilitis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 2/10 (20.00%) |
| Dyspepsia [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 2/19 (10.53%) | 0/13 (0.00%) | 2/18 (11.11%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Enteritis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Eructation [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Flatulence [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Frequent bowel movements [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Gastric disorder [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Gastric ulcer [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Gastrointestinal disorder [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Gastrointestinal pain [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Gastrooesophageal reflux disease [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Gingival bleeding [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Gingival pain [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Gingivitis [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 1/19 (5.26%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Glossodynia [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Haemorrhoids [*1] | | | | | | | | |
| # participants | | | | | | 0/9 (0.00%) | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | | 0/9 (0.00%) | 1/10 (10.00%) |
| Intestinal functional disorder [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Lip haemorrhage [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Mouth ulceration [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Oesophagitis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Oral pain [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Periodontitis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Sensitivity of teeth [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Stomatitis [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| General disorders | | | | | | | | |
| Asthenia [*1] | | | | | | | | |
| # participants affected / at risk | 6/18 (33.33%) | 9/19 (47.37%) | 4/13 (30.77%) | 5/18 (27.78%) | 1/6 (16.67%) | 1/9 (11.11%) | 2/9 (22.22%) | 3/10 (30.00%) |
| Chills [*1] | | | | | | | | |
| # participants affected / at risk | 2/18 (11.11%) | 2/19 (10.53%) | 3/13 (23.08%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 2/9 (22.22%) | 0/10 (0.00%) |
| Fatigue [*1] | | | | | | | | |
| # participants affected / at risk | 10/18 (55.56%) | 8/19 (42.11%) | 5/13 (38.46%) | 7/18 (38.89%) | 3/6 (50.00%) | 3/9 (33.33%) | 5/9 (55.56%) | 2/10 (20.00%) |
| Influenza like illness [*1] | | | | | | | | |
| # participants affected / at risk | 6/18 (33.33%) | 5/19 (26.32%) | 2/13 (15.38%) | 4/18 (22.22%) | 2/6 (33.33%) | 3/9 (33.33%) | 1/9 (11.11%) | 5/10 (50.00%) |
| Injection site erythema [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 2/19 (10.53%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 1/9 (11.11%) | 1/9 (11.11%) | 1/10 (10.00%) |
| Injection site reaction [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 2/19 (10.53%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Irritability [*1] | | | | | | | | |
| # participants affected / at risk | 4/18 (22.22%) | 1/19 (5.26%) | 1/13 (7.69%) | 1/18 (5.56%) | 1/6 (16.67%) | 1/9 (11.11%) | 1/9 (11.11%) | 2/10 (20.00%) |
| Pain [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 1/6 (16.67%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Performance status decreased [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Pyrexia [*1] | | | | | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| # participants affected / at risk | 6/18 (33.33%) | 3/19 (15.79%) | 2/13 (15.38%) | 4/18 (22.22%) | 0/6 (0.00%) | 2/9 (22.22%) | 3/9 (33.33%) | 3/10 (30.00%) |
| Chest discomfort [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Chest pain [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Face oedema [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Feeling cold [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 2/19 (10.53%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Feeling hot [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Injection site bruising [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 2/18 (11.11%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Injection site injury [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Malaise [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Mucosal dryness [*1] | | | | | | | | |
| # participants affected / at risk | 2/18 (11.11%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Non-cardiac chest pain [*1] | | | | | | | | |
| # participants affected / at risk | 2/18 (11.11%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Xerosis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Hepatobiliary disorders** | | | | | | | | |
| Hepatitis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Hyperbilirubinaemia [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Infections and infestations** | | | | | | | | |
| Influenza [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Nasopharyngitis [*1] | | | | | | | | |
| # participants affected / at risk | 2/18 (11.11%) | 2/19 (10.53%) | 0/13 (0.00%) | 2/18 (11.11%) | 1/6 (16.67%) | 1/9 (11.11%) | 1/9 (11.11%) | 2/10 (20.00%) |
| Abscess jaw [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Bronchitis [*1] | | | | | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 2/18 (11.11%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Candidiasis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 2/18 (11.11%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Cystitis [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Erysipelas [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Eyelid infection [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Furuncle [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Gastroenteritis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Genital candidiasis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Gingival abscess [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Gingival infection [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Herpes zoster [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Impetigo [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Lower respiratory tract infection [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Oesophageal candidiasis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Oral candidiasis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Oral fungal infection [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Oral herpes [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Otitis externa [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Otitis media [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Periorbital infection** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Pharyngitis** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Rash pustular** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Respiratory tract infection** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Respiratory tract infection viral** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| **Rhinitis** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Tooth abscess** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 1/9 (11.11%) | 0/10 (0.00%) |
| **Urinary tract infection** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Vulvovaginal mycotic infection** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Injury, poisoning and procedural complications** | | | | | | | | |
| **Ear injury** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Excoriation** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Eye injury** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Facial bones fracture** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Head injury** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Limb injury** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Periorbital haematoma** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Scratch** [*1] | | | | | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Investigations** | | | | | | | | |
| Body temperature increased *1 | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 2/13 (15.38%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Alanine aminotransferase increased *1 | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Aspartate aminotransferase increased *1 | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Blood bilirubin increased *1 | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Blood phosphorus decreased *1 | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Blood uric acid increased *1 | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| ECG signs of myocardial ischaemia *1 | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Haematocrit decreased *1 | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Haemoglobin decreased *1 | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 1/19 (5.26%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Heart rate irregular *1 | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Neutrophil count decreased *1 | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Platelet count decreased *1 | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Weight decreased *1 | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| White blood cell count decreased *1 | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Metabolism and nutrition disorders** | | | | | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Anorexia** [*1] | | | | | | | | |
| **# participants affected / at risk** | **6/18 (33.33%)** | **1/19 (5.26%)** | **1/13 (7.69%)** | **2/18 (11.11%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **3/9 (33.33%)** | **1/10 (10.00%)** |
| **Decreased appetite** [*1] | | | | | | | | |
| **# participants affected / at risk** | **2/18 (11.11%)** | **5/19 (26.32%)** | **1/13 (7.69%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **1/10 (10.00%)** |
| **Dehydration** [*1] | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Diabetes mellitus** [*1] | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **1/19 (5.26%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Hyperglycaemia** [*1] | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Hypertriglyceridaemia** [*1] | | | | | | | | |
| **# participants affected / at risk** | **2/18 (11.11%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **1/9 (11.11%)** | **0/10 (0.00%)** |
| **Hypophosphataemia** [*1] | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **1/6 (16.67%)** | **0/9 (0.00%)** | **1/9 (11.11%)** | **0/10 (0.00%)** |
| **Musculoskeletal and connective tissue disorders** | | | | | | | | |
| **Arthralgia** [*1] | | | | | | | | |
| **# participants affected / at risk** | **5/18 (27.78%)** | **4/19 (21.05%)** | **1/13 (7.69%)** | **3/18 (16.67%)** | **0/6 (0.00%)** | **3/9 (33.33%)** | **4/9 (44.44%)** | **1/10 (10.00%)** |
| **Back pain** [*1] | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **1/19 (5.26%)** | **3/13 (23.08%)** | **1/18 (5.56%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **2/10 (20.00%)** |
| **Bone pain** [*1] | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **2/19 (10.53%)** | **0/13 (0.00%)** | **2/18 (11.11%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Myalgia** [*1] | | | | | | | | |
| **# participants affected / at risk** | **4/18 (22.22%)** | **4/19 (21.05%)** | **4/13 (30.77%)** | **4/18 (22.22%)** | **1/6 (16.67%)** | **1/9 (11.11%)** | **0/9 (0.00%)** | **1/10 (10.00%)** |
| **Pain in extremity** [*1] | | | | | | | | |
| **# participants affected / at risk** | **2/18 (11.11%)** | **1/19 (5.26%)** | **2/13 (15.38%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Flank pain** [*1] | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **1/10 (10.00%)** |
| **Groin pain** [*1] | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Joint ankylosis** [*1] | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Joint swelling** [*1] | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **1/9 (11.11%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Muscle spasms** [*1] | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **1/19 (5.26%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **1/10 (10.00%)** |
| **Muscle tightness** [*1] | | | | | | | | |
| **# participants affected / at risk** | **2/18 (11.11%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Neck pain [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Osteoarthritis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Spinal osteoarthritis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Nervous system disorders | | | | | | | | |
| Disturbance in attention [*1] | | | | | | | | |
| # participants affected / at risk | 2/18 (11.11%) | 1/19 (5.26%) | 1/13 (7.69%) | 1/18 (5.56%) | 0/6 (0.00%) | 1/9 (11.11%) | 1/9 (11.11%) | 1/10 (10.00%) |
| Dizziness [*1] | | | | | | | | |
| # participants affected / at risk | 3/18 (16.67%) | 1/19 (5.26%) | 2/13 (15.38%) | 1/18 (5.56%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Dysgeusia [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 1/19 (5.26%) | 3/13 (23.08%) | 1/18 (5.56%) | 0/6 (0.00%) | 2/9 (22.22%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Headache [*1] | | | | | | | | |
| # participants affected / at risk | 13/18 (72.22%) | 11/19 (57.89%) | 6/13 (46.15%) | 3/18 (16.67%) | 4/6 (66.67%) | 5/9 (55.56%) | 7/9 (77.78%) | 3/10 (30.00%) |
| Amnesia [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Hypoaesthesia [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Intercostal neuralgia [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Lethargy [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Memory impairment [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Migraine [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 1/19 (5.26%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Migraine with aura [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| Paraesthesia [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 2/19 (10.53%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Restless legs syndrome [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Sciatica [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Somnolence** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 1/9 (11.11%) | 0/10 (0.00%) |
| **Syncope** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Psychiatric disorders** | | | | | | | | |
| **Depression** [*1] | | | | | | | | |
| **# participants affected / at risk** | 6/18 (33.33%) | 3/19 (15.79%) | 0/13 (0.00%) | 4/18 (22.22%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Insomnia** [*1] | | | | | | | | |
| **# participants affected / at risk** | 3/18 (16.67%) | 2/19 (10.53%) | 3/13 (23.08%) | 4/18 (22.22%) | 1/6 (16.67%) | 0/9 (0.00%) | 2/9 (22.22%) | 1/10 (10.00%) |
| **Loss of libido** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Mood altered** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 1/19 (5.26%) | 1/13 (7.69%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Nervousness** [*1] | | | | | | | | |
| **# participants affected / at risk** | 3/18 (16.67%) | 1/19 (5.26%) | 2/13 (15.38%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Sleep disorder** [*1] | | | | | | | | |
| **# participants affected / at risk** | 4/18 (22.22%) | 1/19 (5.26%) | 1/13 (7.69%) | 2/18 (11.11%) | 0/6 (0.00%) | 0/9 (0.00%) | 2/9 (22.22%) | 1/10 (10.00%) |
| **Affective disorder** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Aggression** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Agitation** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Alcoholism** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Anxiety** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 1/10 (10.00%) |
| **Dependence** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Depressed mood** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 2/10 (20.00%) |
| **Depressive symptom** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Emotional disorder** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Impulsive behaviour** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Libido decreased** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Listless** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Neurosis** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Tearfulness** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Renal and urinary disorders** | | | | | | | | |
| **Dysuria** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Nephrolithiasis** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Pollakiuria** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Polyuria** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Reproductive system and breast disorders** | | | | | | | | |
| **Epididymitis** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Erectile dysfunction** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Respiratory, thoracic and mediastinal disorders** | | | | | | | | |
| **Cough** [*1] | | | | | | | | |
| **# participants affected / at risk** | 5/18 (27.78%) | 7/19 (36.84%) | 4/13 (30.77%) | 1/18 (5.56%) | 3/6 (50.00%) | 2/9 (22.22%) | 3/9 (33.33%) | 1/10 (10.00%) |
| **Dyspnoea** [*1] | | | | | | | | |
| **# participants affected / at risk** | 5/18 (27.78%) | 4/19 (21.05%) | 3/13 (23.08%) | 1/18 (5.56%) | 1/6 (16.67%) | 2/9 (22.22%) | 2/9 (22.22%) | 4/10 (40.00%) |
| **Dyspnoea exertional** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 1/6 (16.67%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Epistaxis** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 1/9 (11.11%) | 0/10 (0.00%) |
| **Pharyngolaryngeal pain** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 2/19 (10.53%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Hiccups** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Lung disorder** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Nasal congestion** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Nasal dryness** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 2/19 (10.53%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Rhinorrhoea** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Rhonchi** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Sneezing** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 1/9 (11.11%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Throat irritation** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Wheezing** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Skin and subcutaneous tissue disorders** | | | | | | | | |
| **Alopecia** [*1] | | | | | | | | |
| **# participants affected / at risk** | 3/18 (16.67%) | 6/19 (31.58%) | 2/13 (15.38%) | 2/18 (11.11%) | 0/6 (0.00%) | 2/9 (22.22%) | 3/9 (33.33%) | 1/10 (10.00%) |
| **Dry skin** [*1] | | | | | | | | |
| **# participants affected / at risk** | 5/18 (27.78%) | 9/19 (47.37%) | 2/13 (15.38%) | 3/18 (16.67%) | 1/6 (16.67%) | 0/9 (0.00%) | 2/9 (22.22%) | 0/10 (0.00%) |
| **Eczema** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 2/9 (22.22%) | 2/9 (22.22%) | 1/10 (10.00%) |
| **Night sweats** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 2/6 (33.33%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Pruritus** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 3/19 (15.79%) | 2/13 (15.38%) | 5/18 (27.78%) | 0/6 (0.00%) | 3/9 (33.33%) | 3/9 (33.33%) | 3/10 (30.00%) |
| **Pruritus generalised** [*1] | | | | | | | | |
| **# participants affected / at risk** | 5/18 (27.78%) | 1/19 (5.26%) | 2/13 (15.38%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 1/9 (11.11%) | 2/10 (20.00%) |
| **Rash** [*1] | | | | | | | | |
| **# participants affected / at risk** | 1/18 (5.56%) | 3/19 (15.79%) | 3/13 (23.08%) | 4/18 (22.22%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 1/10 (10.00%) |
| **Urticaria localised** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Cold sweat** [*1] | | | | | | | | |
| **# participants affected / at risk** | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| **Dermatitis** [*1] | | | | | | | | |
| **# participants affected / at risk** | 2/18 (11.11%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| **Dermatitis allergic** [*1] | | | | | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Dermatitis atopic [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Erythema [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 2/18 (11.11%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Hyperhidrosis [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Hypoaesthesia facial [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 1/13 (7.69%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Lichen planus [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Nail discolouration [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Photosensitivity reaction [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Purpura [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Rash erythematous [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Rash generalised [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Rash macular [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Seborrhoeic dermatitis [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Skin burning sensation [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 1/9 (11.11%) | 0/10 (0.00%) |
| Skin fissures [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 1/19 (5.26%) | 0/13 (0.00%) | 1/18 (5.56%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Skin irritation [*1] | | | | | | | | |
| # participants affected / at risk | 1/18 (5.56%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Vascular disorders | | | | | | | | |
| Deep vein thrombosis [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 1/19 (5.26%) | 0/13 (0.00%) | 0/18 (0.00%) | 0/6 (0.00%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |
| Flushing [*1] | | | | | | | | |
| # participants affected / at risk | 0/18 (0.00%) | 0/19 (0.00%) | 0/13 (0.00%) | 0/18 (0.00%) | 1/6 (16.67%) | 0/9 (0.00%) | 0/9 (0.00%) | 0/10 (0.00%) |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Hot flush** * 1 | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Hypertension** * 1 | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **1/19 (5.26%)** | **0/13 (0.00%)** | **1/18 (5.56%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **1/9 (11.11%)** | **0/10 (0.00%)** |
| **Hypotension** * 1 | | | | | | | | |
| **# participants affected / at risk** | **0/18 (0.00%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **1/10 (10.00%)** |
| **Phlebitis** * 1 | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **1/10 (10.00%)** |
| **Raynaud's phenomenon** * 1 | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |
| **Vasculitis** * 1 | | | | | | | | |
| **# participants affected / at risk** | **1/18 (5.56%)** | **0/19 (0.00%)** | **0/13 (0.00%)** | **0/18 (0.00%)** | **0/6 (0.00%)** | **0/9 (0.00%)** | **0/9 (0.00%)** | **0/10 (0.00%)** |

* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA Version 10.1

## Limitations and Caveats

Hide Limitations and Caveats

| **Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data** |
|---|
| No text entered. |

## More Information

Hide More Information

**Certain Agreements:**

| |
|---|
| Principal Investigators are **NOT** employed by the organization sponsoring the study. |
| There **IS** an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. |
| The agreement is:<br>☑ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **less than or equal to 60 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.<br>☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **more than 60 days but less than or equal to 180 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.<br>☐ Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. |

**Results Point of Contact:**

Name/Title: Global Clinical Development Manager
Organization: Jan-Cil France
e-mail: ClinicalTrialDisclosure@its.jnj.com

**Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):**

Lenz O, de Bruijne J, Vijgen L, Verbinnen T, Weegink C, Van Marck H, Vandenbroucke I, Peeters M, Simmen K, Fanning G, Verloes R, Picchio G, Reesink H. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology. 2012 Nov;143(5):1176-8.e1-6. doi: 10.1053/j.gastro.2012.07.117. Epub 2012 Aug 8.

Manns M, Reesink H, Berg T, Dusheiko G, Flisiak R, Marcellin P, Moreno C, Lenz O, Meyvisch P, Peeters M, Sekar V, Simmen K, Verloes R. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther. 2011;16(7):1021-33.

doi: 10.3851/IMP1894.

| | |
|---|---|
| Responsible Party: | Tibotec Pharmaceuticals, Ireland |
| ClinicalTrials.gov Identifier: | NCT00561353 History of Changes |
| Obsolete Identifiers: | NCT00614185 |
| Other Study ID Numbers: | CR012607<br>**TMC435350-TiDP16-C201** ( Other Identifier: Tibotec Pharmaceuticals, Ireland ) |
| Study First Received: | November 19, 2007 |
| Results First Received: | December 18, 2013 |
| Last Updated: | May 14, 2014 |
| Health Authority: | Germany: Bundesinstitut für Arzneimittel und Medizinprodukte<br>Great Britain: Medicines and Healthcare Products Regulatory Agency<br>Belgium: Federal Agency for Medicinal Products and Health Products<br>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products<br>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)<br>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |

**Disclaimer**

Information in this posting shall not be considered to be a claim for any marketed Product. Some information in this posting may differ from the approved labeling for the Product. Please refer to the full prescribing information for indications and proper use of the product.